



Contents lists available at ScienceDirect

Journal of Infection

journal homepage: www.elsevier.com/locate/jinf

Nasopharyngeal Microbiota as an early severity biomarker in COVID-19 hospitalised patients



Maria Paz Ventero^{a,1}, Oscar Moreno-Perez^{b,c,1}, Carmen Molina-Pardines^{a,*},
Andreu Paytuví-Gallart^{d,e}, Vicente Boix^{f,c}, Isabel Escribano^a, Irene Galan^g,
Pilar González-delaAleja^f, Mario López-Pérez^{h,a}, Rosario Sánchez-Martínezⁱ,
Esperanza Merino^{f,2}, Juan Carlos Rodríguez^{a,h,2}

^a Microbiology Service, Alicante General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain

^b Endocrinology and Nutrition department, Alicante General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain

^c Clinical Medicine department, Miguel Hernández University, Elche, Spain

^d Sequentia Biotech, Carrer Comte d'Urgell 240, 08036 Barcelona, Spain

^e Open University of Catalonia (UOC), Rambla del Poblenou, 156, 08018 Barcelona, Spain

^f Unit of Infectious Diseases, Alicante General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain

^g Pneumology department, Alicante General University Hospital - Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain

^h Evolutionary Genomics Group, División de Microbiología, Universidad Miguel Hernández, Spain

ⁱ Internal Medicine department, Alicante General University Hospital - Alicante Institute of Sanitary and Biomedical Research (ISABIAL), Alicante, Spain

ARTICLE INFO

Article history:

Accepted 21 December 2021

Available online 25 December 2021

Keywords:

Microbiota
COVID-19
SARS-COV-2
Severity
Biomarker
Prognosis

SUMMARY

This study aimed to analyse the diversity and taxonomic composition of the nasopharyngeal microbiota, to determine its association with COVID-19 clinical outcome. To study the microbiota, we utilized 16S rRNA sequencing of 177 samples that came from a retrospective cohort of COVID-19 hospitalized patients. Raw sequences were processed by QIIME2. The associations between microbiota, invasive mechanical ventilation (IMV), and all-cause mortality were analysed by multiple logistic regression, adjusted for age, gender, and comorbidity. The microbiota α diversity indexes were lower in patients with a fatal outcome, whereas the β diversity analysis showed a significant clustering in these patients. After multivariate adjustment, the presence of *Selenomonas* spp., *Filifactor* spp., *Actinobacillus* spp., or *Chroococcidiopsis* spp., was associated with a reduction of more than 90% of IMV. Higher diversity and the presence of certain genera in the nasopharyngeal microbiota seem to be early biomarkers of a favourable clinical evolution in hospitalized COVID-19 patients.

© 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Introduction

In this time of pandemic finding early prognostic markers of COVID-19 severity is of utmost importance [1,2]. It is known that poor outcomes related to COVID-19 are not only a consequence of the viral infection, but are also related to an aberrant host immune response, including the vast release of cytokines by the immune system, leading to uncontrolled inflammation and multi-organ failure [3].

Several risk or prognostic factors, such as genetic factors, comorbidities, age, sex, and geographical location, have been associated with COVID-19 severity [2,4,5]. Taken together, these characteristics could have a determining role in promoting immune responses and preventing an excessive anti-viral immune reaction.

Microbiota may be related to or influence the natural history of certain infectious diseases [6]. For example, in *Clostridioides difficile* infection, a lower diversity of microbiota and a decrease in several families are associated with the incidence and clinical evolution of the disease [7]. Likewise, the respiratory microbiota has also been correlated with the clinical evolution of chronic respiratory diseases [8] and respiratory viral infections [9].

Regarding microbiota and COVID-19 pathology, many published studies have focused on the differences between COVID-19 and non-COVID-19 patients, suggesting a possible role of the gut or

* Corresponding author.

E-mail address: carmenmolinapardines@gmail.com (C. Molina-Pardines).

¹ These authors contributed to the manuscript equally and share the first authorship

² Esperanza Merino and Juan Carlos Rodríguez are Joint Senior Authors

respiratory microbiota in susceptibility to SARS-CoV-2 infection [10,11]. Additionally, some studies have shown a relationship between the composition of the gut and respiratory microbiota and disease severity [12]. This relationship appears to be mainly based on the capacity of the microbiota to modulate the immune response [13,14], through modification of the gut-lung axis [12,15,16], and to alter the expression of angiotensin-converting enzyme 2 (ACE2) receptors, which are used by SARS-CoV-2 to enter host cells [17,18].

The available evidence suggests a potential role of microbiota in susceptibility to SARS-CoV-2 infection and COVID-19 severity, but longitudinal studies evaluating the microbiota as a prognostic factor for severity of disease progression are lacking [19–22]. The data regarding the association between nasopharyngeal microbiota features and disease severity are scarce and limited in terms of showing a decrease in α diversity or identifying specific genera with relevance to critical illness [23,24]. Since the sampling of this location is very accessible, with the nasopharyngeal aspirate swab diagnostic confirmation procedure able to obtain this information, it should be a priority to address the relationship between nasopharyngeal microbiota and COVID-19 outcomes. In this line, it would be interested replicate this results in saliva samples, since saliva has demonstrated a high similarity in terms of SARS-CoV-2 detection [25–27], and it is easier and less unpleasant to be obtained.

This study aimed to analyse the nasopharyngeal microbiota from hospitalised COVID-19 patients, to determine the relationship between the microbiota and SARS-CoV-2 infection clinical outcomes and to identify features or genera that could be used as severity prognostic markers.

Materials and methods

Patients and study design and setting

A retrospective cohort of adult patients with COVID-19, hospitalised in a tertiary centre (Alicante University General Hospital, Spain) from February 27th 2020 to January 22nd 2021, was studied. SARS-CoV-2 infection was confirmed by the RT-PCR-COBAS 6800 System (Roche Molecular Systems, Branchburg, NJ, United States). At hospital admission one nasopharyngeal specimen per patient was obtained, stored at -80°C and later analysed.

Of the 1526 patients hospitalised in the study period, nasopharyngeal samples from 324 patients were randomly processed and preserved. Due to the available economic resources, sixty percent of the samples were randomly sampled for processing; 17 samples did not correspond to the first PCR sample, so they were discarded. Finally, 177 patients were included in the study (see supplementary material, Figure S1).

Variables and data collection

The clinical features, comorbidity, laboratory and radiological tests, prescribed therapies, and outcome during the acute phase of the infection by SARS-CoV-2 were extracted from the digital medical record.

The main explanatory variables of the analysis were the microbiota diversity, measured by the α and β diversity indexes, and the taxonomic composition, expressed by the differentially represented genera.

Primary Outcomes: Invasive mechanical ventilation (IMV) and all-cause mortality.

DNA isolation and microbiota amplicon next-generation sequencing (NGS)

The nasopharyngeal samples frozen at -80°C were used for DNA isolation with the QIAamp MiniElute Virus Spin Kit (Qiagen, Hilden, Germany), following the protocol recommended by the manufacturer. The DNA obtained was quantified with a Qubit 4 Fluorometer, using a Qubit dsDNA HS Assay Kit (ThermoFisher Scientific, Massachusetts, United States). The microbiota amplicon sequencing was performed following the protocol of the 16S Metagenomics Sequencing Library Preparation recommended by Illumina. The V3 and V4 region from 16S rRNA gene were amplified by PCR, and then the fragments obtained were sequenced in the MiSeq system with V3 reagents (600 cycle, 2×300 bp).

Bioinformatic analyses

The raw reads obtained from the NGS were analysed using QIIME2 (2021.2 version) [28]. The denoising was performed with the plugin DADA2 and to avoid contamination and false positives a BLAST against the database of human genome of NCBI was performed, as well as singletons were removed. The taxonomy was assigned using the SILVA Database (Release 132) [29]. Regarding the microbiota analyses, the Shannon, Pielou, and Simpson indexes were calculated to study the α diversity, and the UniFrac weighted distance plus PCoA were performed to analyse the β diversity. The genera that were differentially represented between severity groups (main outcomes present or not) were determined using the R package DESeq2 (4.1.0 version) [30]. The linear model obtained by DESeq2 was adjusted by the prescription of antibiotic treatment 3 months earlier.

Statistical analysis

Categorical and continuous variables are given as frequencies (percentages) and as the median (interquartile range), respectively. Patients of the global cohort that were included and excluded were compared by Mann-Whitney's U, chi-squared, and Fisher's exact tests. Cumulative incidences of outcomes (95% confidence intervals (95%CI)) were registered. The final date of follow-up was March 1, 2021, unless censored. The differences between groups in the β diversity were assessed using the PERMANOVA test. Associations were evaluated by a chi-squared test. Multiple logistic regression models adjusted for age, gender, and comorbidity were built to evaluate the association between microbiota diversity indexes or the differentially represented genus (obtained by DESeq2) with the primary outcomes, and the odds ratios (OR) with the 95%CI were estimated. IBM SPSS Statistics v25 (Armonk, NY) was used for the analyses. $P < 0.050$ defined statistical significance.

Ethics statement and data availability

This project was performed in the Clinical and Biomedical Research Institute of Alicante (ISABIAL), under the written approval of the Ethics Committee of Clinical Research with Drugs (in Spanish, CEIm) of the General University Hospital of Alicante (Ref CEIm approval: PI2020–052).

The raw data from the sequencing are available in the National center for Biotechnology Information Database (NCBI), under the Bioproject accession number PRJNA754005.

Results

Participants and descriptive data

A total of 177 patients were included in the study. The study population and the global cohort of 1526 patients hospitalised

Table 1
Demographic characteristics, comorbidities, clinical presentation, and clinical outcomes.*.

	Population[n = 177]
Demographics	
Age, median (IQR), years	68 (52–80)
Age ≥ 65 years old,% (N)	55.9 (99/177)
Males,% (N)	57.6 (102/177)
Nosocomial,% (N)	1.7 (3/177)
Long-term care resident,% (N)	4 (7/177)
Health professional,% (N)	4 (7/177)
Waves First (1.02.2020 – 31.05.2020),% (N) Second (1.06.2020 – 15.12.2020),% (N) Third (16.12.2020 – 31.03.2021),% (N)	54.2 (96/177) 31.1 (55/177) 14.7 (26/177)
Antibiotic therapy in the previous 3 months	28.8 (51/177)
Comorbidities	
Hypertension,% (N)	55.9 (99/177)
Diabetes,% (N)	26.6 (47/177)
Current or former Smoker,% (N)	20.6 (70/177)
Obesity,% (N)	39.7 (56/141)
Chronic respiratory disease,% (N)	21.6 (38/177)
Immunosuppression,% (N)	4 (7/177)
Charlson comorbidity index, median (IQR)	3 (1–6)
Charlson index ≥3,% (N)	59.3% (105/177)
10-years expected survival ^a	53.3 (1.6–90.1)
Clinical Presentation	
Median time (IQR) from symptom to hospitalization, days ^b	6 (3–7)
Fever,% (N)	67.2 (119/177)
Cough,% (N)	26.0 (46/177)
Dyspnoea,% (N)	57.6 (102/177)
Diarrhoea,% (N)	25 (44/177)
Confusion,% (N)	9.6 (17/177)
Fatigue,% (N)	41.0 (71/173)
Myalgias-arthralgias,% (N)	30.1 (52/173)
Anosmia-dysgeusia,% (N)	6.9 (12/173)
Initial Assessment	
Oximetry <94% at room air,% (N)	43.7% (73/167)
PaO ₂ :FiO ₂ , median (IQR)	332 (272–404)
Respiratory rate, breaths/min, median (IQR)	18 (16–24)
Systolic BP, mmHg, median (IQR)	130 (118–145)
Diastolic BP, mmHg, median (IQR)	78 (68–89)
Temperature, °C, median (IQR)	36.9 (36.3–37.7)
Heart rate, beats/min, median (IQR)	92 (81–102)
eGFR, ml/min/m ² , median (IQR)	73 (47–90)
Lymphocytes, per mm ³ , median (IQR)	910 (700–1370)
Lymphopenia,% (N)	44.3 (78/176)
C-reactive protein > 10 mg/dL,% (N)	33.1 (55/175)
Procalcitonin > 0.5 ng/mL,% (N)	12.4 (20/161)
Ferritin > 500 mg/L,% (N)	59.8 (98/164)
Lactate dehydrogenase > 250 U/L,% (N)	33.9 (53/156)
D-dimers > 1 mg/mL,% (N)	33.1 (53/160)
Interleukin 6 ≥ 10 pg/mL,% (N)	77.7 (101/130)
Troponin T > 14 ng/L,% (N)	49.4 (77/176)
Brain natriuretic peptide > 125 pg/mL,% (N)	53.5 (84/157)
Potassium mmol/L, median (IQR)	4.1 (3.8–4.4)
Pneumonia on X-rays,% (N)	89.2 (157/176)
Opacities >50% of lung surface on X-rays,% (N)	21.5 (38/177)
Treatment	
Corticosteroids,% (N)	46.3% (82/177)
Remdesivir,% (N)	3.9% (7/177)
Tocilizumab,% (N)	23.7% (42/177)
Outcomes	
Non-invasive mechanical ventilation requirement,% (N)	23.1 (41/177)
Invasive mechanical ventilation requirement,% (N)	11.3 (20/177)
Mortality,% (N)	17.5 (31/177)

* Data shown as%, median (interquartile range, IQR), unless specified otherwise. In bold, statistically significant differences. Percentages may not total 100 because of rounding.

^a 10-years expected survival derived from Charlson comorbidity index score.

^b Days of symptoms before admission. OR: odds ratio, 95%CI: 95% confidence interval.

while the study lasted were similar in age, gender, comorbidities, extent of infiltrates on chest radiograph, dexamethasone use, duration of hospitalization, and outcomes: IMV and mortality ($p > 0.05$).

Table 1 shows the general characteristics of the study population and the main features of the COVID-19 acute phase infection and its clinical evolution. The patients had a median age of 68.0

years (IQR) (52.0–80.0); 57.6% were males and 59.3% had a Charlson comorbidity index ≥ 3 . They were assessed in the emergency department after a median of 6 [3–7] days of symptoms, and 89.2% had pneumonia. Fifty-one patients (28.8%) had received antibiotic therapy in the 3 months prior to their hospital admission, for a median of 5 [2–6] days. The mortality rate was 17.5% (95%CI, 12.6–23.7) (31/177), and 11.3% (95%CI, 7.4–16.8) (20/177) required IMV.




Fig. 1. Diversity analysis: Boxplots obtained for the Shannon index (A), Pielou index (B), and Simpson index (C). PCoA (principal coordinates analysis) for the β diversity distribution along the samples (D).

Diversity analysis and outcomes

The α diversity indexes were lower in patients with a fatal outcome: Shannon 3.59[2.86–4.42] vs. 4.39[3.12–5.14], $p = 0.014$; Pielou 0.58[0.50–0.67] vs. 0.71[0.55–0.79], $p = 0.007$; and Simpson index 0.80[0.62–0.88] vs. 0.89[0.76–0.94], $p = 0.018$ (Figs 1A, 1B, and 1C). The protective effect of a greater microbiota diversity persisted for the Shannon (adjusted OR (aOR) 0.654 [95%CI 0.448–0.956], $p = 0.028$) and Pielou indexes (aOR 0.055[95%CI 0.003–0.823], $p = 0.036$) after adjustment for age, gender, and comorbidities. The β diversity analysis showed a significant clustering ($p = 0.014$), grouping together the fatal outcome patients (Fig 1D). In the case of IMV, neither the α diversity indexes nor β diversity analyses showed any significant differences.

Taxonomic analysis and outcomes

Streptococcus spp. (14.14%), *Staphylococcus* spp. (12.12%), and *Corynebacterium* spp. (9.11%) were the genera more abundant in COVID-19 patients, without significant differences between patients with IMV or a fatal outcome (see supplementary material, Figure S2, Table S1). By group, there were 34.20% (483/1412) taxa shared between IMV/non-IMV subpopulations, 4.67% (66/1412) taxa exclusively found in IMV patients, and 61.12% (863/1412) taxa only detected in non-IMV patients (Fig 2A).

Regarding fatal outcome, the results were similar. The shared taxa comprised 41.57% (587/1412), taxa exclusively found in the exitus subpopulation were 6.8% (96/1412), and in survivors 51.2% (729/1412) (Fig 2B).




Fig. 2. Taxonomic analysis: Venn diagrams for IMV (A), and fatal outcome (B), and relative abundances of differential genera for IMV (C), and fatal outcome subpopulations (D). Relative abundances are shown in logarithmic scale. IMV: invasive mechanical ventilation, FO: Fatal outcome.

Differently represented genera and outcomes

This study was performed to identify differential genera between the subpopulations with and without specific outcomes. We found that *Selenomonas* spp. ($\text{LogFC} = 23.96$; $p < 0.0001$), *Filifactor* spp. ($\text{LogFC} = 23.51$; $p < 0.0001$), *Actinobacillus* spp. ($\text{LogFC} = 24.86$; $p < 0.0001$) and *Chroococcidiopsis* spp. ($\text{LogFC} = 22.31$; $p < 0.0001$) were significantly more abundant in non-IMV patients (Fig 2C, Supplementary Table S2). The presence of *Selenomonas* spp., *Filifactor* spp., *Actinobacillus* spp., or *Chroococcidiopsis* spp., was associated with a reduced risk of IMV (OR 0.062 [95%CI 0.01–0.47], $p = 0.007$). This protective association persisted after adjustment for the main confounders in the multivariate model (Fig 3).

For fatal outcomes, *Actinobacillus* spp. ($\text{LogFC} = 24.30$; $p < 0.0001$), *Citrobacter* spp. ($\text{LogFC} = 25.21$; $p < 0.0001$), *Craurococcus* spp. ($\text{LogFC} = 22.77$; $p < 0.0001$), and *Moheibacter* spp. ($\text{LogFC} = 22.7$; $p < 0.0001$) were significantly more abundant in non-exit patients (Fig 2D, Supplementary Table S2). The presence of *Actinobacillus* spp., *Citrobacter* spp., *Craurococcus* spp., or *Moheibacter* spp., was associated with a reduced risk of a fatal outcome (OR 0.309 [95%CI 0.10–0.93], $p = 0.037$). This association did not persist after adjustment for the main confounders in the multivariate model (Fig 3).

Discussion

Recently, several studies assessing the relationship between the gut microbiome and the severity of COVID-19 have been published [31,32]. However, to our knowledge, this is the first study that has evaluated nasopharyngeal microbiota at the time of admission as a prognosis biomarker of severity of disease progression in the acute infection phase of SARS-CoV-2, in a large cohort of hospitalised patients with COVID-19. The assessment showed a significant decrease of all diversity indexes studied (Shannon, Pielou, and Simpson) in patients with a final fatal outcome, linking an initial low microbiota diversity with COVID-19 severity. The presence of four specific genera, *Selenomonas* spp., *Filifactor* spp., *Actinobacillus* spp. or *Chroococcidiopsis* spp., was associated with a reduction of more than 90% of IMV, regardless of age, gender, or comorbidity. The presence of *Actinobacillus* spp., *Citrobacter* spp., *Craurococcus* spp. or *Moheibacter* spp. was associated with a 70% reduction in mortality, but this relationship did not persist after adjustment for the main confounders.

The relationship between the microbiota and COVID-19 is an active and expanding field of research. Previous studies have been focused on the differences of the gut microbiota between COVID-19




Fig. 3. Predictors of Invasive Mechanical Ventilation and In-Hospital Death from Multivariable Logistic-Regression Analysis. The 95% confidence intervals (CIs) of the odds ratios have been adjusted for multiple testing.

and non-COVID19 patients, or its correlation with severity inflammatory markers [10,11]. However, there has been limited investigation into the relationship between microbial communities and COVID-19 clinical outcome.

Regarding COVID-19 and the gut microbiome, Gu et al. [33] reported that COVID-19 patients had a lower diversity microbiota (Shannon and Chao1 index) than healthy controls; also, several microorganisms (*Streptococcus* spp., *Rothia* spp., *Veillonella* spp. and *Actinomyces* spp.) were identified that could be used as COVID-19 biomarkers. According to these data, Zuo et al. [34], using the Bray-Curtis dissimilarities test, described alterations in the gut microbiome at the whole genome level, since their COVID-19 patients were more heterogeneous than healthy controls. Yeoh et al. [12] found that specific genera, such as *Bifidobacterium adolescentis*, *Eubacterium rectale*, and *Faecalibacterium prausnitzii*, were depleted in the COVID-19 cohort when compared with non-COVID-19 patients, and were negatively correlated with the inflammatory marker CXCL10. The same correlation was reported by Zou et al. [34]. Likewise, Gou et al. [35] showed that the *Bacteroides* genus, and specifically *B. ovatus*, was associated with inflammatory cytokines such as IL-6, TNF- α and IFN- γ [35]. These depleted species in COVID-19 patients are known to play immunomodulatory roles in the human gastrointestinal system [36].

In terms of the association of the upper respiratory tract microbiome and SARS-COV-2 infection, the studies performed to date have included small cohorts of patients. Braun et al. [37] ($n = 33$), De Maio et al. [38] ($n = 40$), and Liu et al. [39] ($n = 9$) showed no significant differences in the nasopharyngeal microbial com-

munity between COVID-19 and control patients using α - β diversity and taxonomic compositional analysis. Whereas Mostafa et al. [40] ($n = 50$) and Engen et al. [41] ($n = 19$) reported a lower α diversity (Chao1, Shannon, and Simpson indexes) in COVID-19 compared to healthy patients, and both groups showed significant dissimilarities in β diversity. Therefore, there is controversy regarding lung and nasopharyngeal microbiota composition on SARS-CoV2 infection.

Regarding microbiota and COVID-19 severity, Ma et al. [23] explored the oropharyngeal microbiome in COVID-19 patients ($n = 31$) with various severities (mild, moderate, severe, or critical) compared with flu patients ($n = 29$) and healthy controls ($n = 28$) using high-throughput metagenomics. They showed that critical COVID-19 patients presented with a significant diminution in α diversity (Shannon index), while noncritical patients exhibited no significant change from the normal group.

The present work pioneered the analysis of the nasopharyngeal microbiota (using 16S rRNA gene sequencing), in a large cohort of hospitalised patients with COVID-19, as a prognosis biomarker. The lower diversity in patients with a fatal outcome is in agreement with the hypothesis that low microbiota diversity is associated with the development of several pathologies [42,43], and high diversity is associated with lower severity [44].

A study performed with 24 critically ill COVID-19 patients and 24 non-COVID-19 patients with pneumonia [45] showed taxonomical differences between the lung microbiota of COVID-19 and non-COVID-19 patients. The characteristic microorganisms of COVID-19 patients were *Pseudomonas alcaligenes*, *Sphingobacterium*

spp., *Clostridium hiranonis* and *Acinetobacter schindleri*. While the genera that characterised the lung microbiota in the COVID-19-negative patients were *Streptococcus* spp., *Haemophilus* or *Selenomonas* spp. Regarding the upper respiratory tract microbiota, Ma et al. [23] found increased ratios of *Klebsiella* sp., *Acinetobacter* sp., and *Serratia* sp. were correlated with both disease severity and elevated systemic inflammation markers (neutrophil–lymphocyte ratio). Along the same lines, *Prevotella* spp. was also linked to COVID-19 severity, which has been hypothesised to suggest a possible relationship with the inflammatory response [24].

Our taxonomic analysis identified several microorganisms, such as *Selenomonas*, *Filifactor*, *Actinobacillus*, and *Chroococcidiopsis* SAG 2023, related to IMV, and *Craurococcus*, *Actinobacillus*, *Citrobacter* and *Moheibacter* related to a fatal outcome. Future research to determine their roles in COVID-19 development and evolution is required.

Our study has several limitations, this was an observational, retrospective, single-centre study, and collection of data was not standardized in advance. The sample size and the absence of differences in the characteristics of the global cohort of patients admitted to our hospital during the duration of the study reinforce the present data. Multiple factors can condition changes in microbiota, including the use of antibiotics. Nonetheless, the design of the statistical analysis adjusted for the use of antibiotic therapy in the 3 months prior to the inclusion of the study, allowing us to limit this bias. The exclusion of these patients from the study would have greatly limited the external validity of our results. Finally, the 16S ribosomal RNA amplicon sequencing approach to study the microbiota could introduce bias in the obtained data because this method does not allow the study of the whole microbiome, but only the genera amplified by PCR. Nevertheless, it is the most common technique to study microbiota in clinical samples. Moreover, the microbiota bioinformatics analysis has not been standardized yet, which hampered comparison interpretations of our results.

In summary, the higher diversity found in patients without IMV or a fatal outcome, together with the presence of certain genera in the nasopharyngeal microbiota, seemed to be an early biomarker of a favourable clinical evolution in a cohort of Mediterranean hospitalised patients with SARS-CoV-2 infection. Our findings have potential clinical relevance due to the feasibility and low cost of developing rapid molecular techniques to evaluate the diversity and detect these genera at the time of admission. These data, taken together with other prognostic markers already being implemented, may allow identifying patients with a good prognosis (i.e., a 70–90% reduction in unfavourable clinical outcomes). Considering the clinical significance of these findings and the ease of their application in daily practice, further investigation to confirm these data could be very relevant for improving COVID-19 management.

Funding

This work was supported by the “Health Institute Carlos III” [grant number COV20_00236] and by the “Alicante Institute of Health and Biomedical Research (ISABIAL)” [grant number exp: 2020-0356].

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgements

Not applicable. Thanks to the COVID19-ALC Research Group of the General University Hospital of Alicante.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jinf.2021.12.030.

References

- [1] Liu J, Liu S. The management of coronavirus disease 2019 (COVID-19). *J Med Virol* 2020;**92**:1484–90. doi:10.1002/jmv.25965.
- [2] Andrés M, Leon-Ramirez JM, Moreno-Perez O, Sánchez-Payá J, Gayá I, Esteban V, et al. Fatality and risk features for prognosis in COVID-19 according to the care approach - a retrospective cohort study. *PLoS ONE* 2021;**16**:e0248869. doi:10.1371/journal.pone.0248869.
- [3] Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* 2020;**20**:363–74. doi:10.1038/s41577-020-0311-8.
- [4] Moreno-P O, Leon-Ramirez JM, Fuertes-Kenneally L, Perdiguerro M, Andres M, Garcia-Navarro M, et al. Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: a case series of 306 Mediterranean patients. *Int J Infect Dis* 2020;**100**:449–54. doi:10.1016/j.ijid.2020.09.033.
- [5] Dai CL, Kornilov SA, Roper RT, Cohen-Cline H, Jade K, Smith B, et al. Characteristics and factors associated with coronavirus disease 2019 infection, hospitalization, and mortality across race and ethnicity. *Clin Infect Dis* 2021. doi:10.1093/cid/ciab154.
- [6] Pflughoef KJ, Versalovic J. Human microbiome in health and disease. *Annu Rev Pathol Mech Dis* 2012;**7**:99–122. doi:10.1146/annurev-pathol-011811-132421.
- [7] Berkell M, Mysara M, Xavier BB, van Werkhoven CH, Monsieurs P, Lamens C, et al. Microbiota-based markers predictive of development of *Clostridioides difficile* infection. *Nat Commun* 2021;**12**:1–14. doi:10.1038/s41467-021-22302-0.
- [8] Budden KF, Shukla SD, Rehman SF, Bowerman KL, Keely S, Hugenholtz P, et al. Functional effects of the microbiota in chronic respiratory disease. *Lancet Respir Med* 2019;**7**:907–20. doi:10.1016/S2213-2600(18)30510-1.
- [9] Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. *Front Immunol* 2018;**9**:2640. doi:10.3389/fimmu.2018.02640.
- [10] Marcialis MA, Bardanzellu F, Fanos V. Microbiota and Coronavirus Disease: Which came first, the chicken or the egg? *Clin Infect Dis* 2020. doi:10.1093/cid/ciaa965.
- [11] Yamamoto S, Saito M, Tamura A, Prawisuda D, Mizutani T, Yotsuyanagi H. The human microbiome and COVID-19: a systematic review. *PLoS ONE* 2021;**16**:e0253293. doi:10.1371/journal.pone.0253293.
- [12] Yeoh YK, Zuo T, Lui GCY, Zhang F, Liu Q, Li AYL, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. *Gut* 2021;**70**:698–706. doi:10.1136/gutjnl-2020-323020.
- [13] Khatiwada S, Subedi A. Lung microbiome and coronavirus disease 2019 (COVID-19): possible link and implications. *Hum Microbiome J* 2020;**17**. doi:10.1016/j.humic.2020.100073.
- [14] van der Lelie D, Taghavi S. COVID-19 and the Gut Microbiome: more than a Gut Feeling. *MSystems* 2020;**5**. doi:10.1128/mSystems.00453-20.
- [15] Din AU, Mazhar M, Wasim M, Ahmad W, Bibi A, Hassan A, et al. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role. *Biomed Pharmacother* 2021;**133**. doi:10.1016/j.biopha.2020.110947.
- [16] Kaźmierczak-Siedlecka K., Vitale E., Makarewicz W. COVID-19 – gastrointestinal and gut microbiota-related aspects. n.d. 2021
- [17] Ahlawat S, Asha Sharma KK. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection. *Virus Res* 2020;**286**:198103. doi:10.1016/j.virusres.2020.198103.
- [18] Koester ST, Li N, Lachance DM, Morella NM, Dey N. Variability in digestive and respiratory tract Ace2 expression is associated with the microbiome. *PLoS ONE* 2021;**16**:e0248730. doi:10.1371/journal.pone.0248730.
- [19] He Y, Wang J, Li F, Shi Y. Main clinical features of COVID-19 and potential prognostic and therapeutic value of the microbiota in SARS-CoV-2 infections. *Front Microbiol* 2020;**11**:1302. doi:10.3389/fmicb.2020.01302.
- [20] Ferreira C, Viana SD, Reis F. Is gut microbiota dysbiosis a predictor of increased susceptibility to poor outcome of COVID-19 patients? An update. *Microorganisms* 2021;**9**:1–12. doi:10.3390/microorganisms9010053.
- [21] Hernández-Terán A, Mejía-Nepomuceno F, Herrera MT, Barreto O, García E, Castillejos M, et al. Dysbiosis and structural disruption of the respiratory microbiota in COVID-19 patients with severe and fatal outcomes. *Sci Reports* 2021;**11**:1–13. doi:10.1038/s41598-021-00851-0.
- [22] Ren L., Wang Y., Zhong J., Li X., Xiao Y., Li J., et al. Dynamics of the Upper Respiratory Tract Microbiota and its Association with Mortality in COVID-19. <https://doi.org/10.1164/Rccm202103-08140C> 2021. <https://doi.org/10.1164/RCCM.202103-08140C>.
- [23] Ma S, Zhang F, Zhou F, Li H, Ge W, Gan R, et al. Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19. *Signal Transduct Target Ther* 2021;**6**:1–11. doi:10.1038/s41392-021-00614-3.
- [24] Ventero MP, Cuadrat RRC, Vidal I, Andrade BGN, Molina-Pardines C, Haro-Moreno JM, et al. Nasopharyngeal microbial communities of patients infected with SARS-CoV-2 that developed COVID-19. *Front Microbiol* 2021;**12**:637430. doi:10.3389/fmicb.2021.637430.

- [25]. Carrouel F, Valette M, Perrier H, Bouscambert-Duchamp M, Dussart C, Tramini P, et al. Performance of self-collected saliva testing compared with nasopharyngeal swab testing for the detection of SARS-CoV-2. *Viruses* 2021;**13**:895. doi:10.3390/V13050895.
- [26]. Boerger AC, Buckwalter S, Fernholz EC, Jannetto PJ, Binnicker MJ, Reed K, et al. Evaluation of self-collected midturbinate nasal swabs and saliva for detection of sars-cov-2 rna. *J Clin Microbiol* 2021;**59**. doi:10.1128/JCM.00848-21/ASSET/D740D9AD-B977-428E-B618-18135BB129A8/ASSETS/IMAGES/LARGE/JCM.00848-21-F002.JPG.
- [27]. Alemany A, Millat-Martinez P, Ouchi D, Corbacho-Monné M, Bordoy AE, Esteban C, et al. Self-collected mid-nasal swabs and saliva specimens, compared with nasopharyngeal swabs, for SARS-CoV-2 detection in mild COVID-19 patients. *J Infect* 2021. doi:10.1016/j.jinf.2021.09.012.
- [28]. Kuczynski J, Stombaugh J, Walters WA, González A, Caporaso JG, Knight R. Using QIIME to analyze 16S rRNA gene sequences from microbial communities. *Curr Protoc Microbiol* 2012 Chapter 1:Unit 1E.5. doi:10.1002/9780471729259.mc01e05s27.
- [29]. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res* 2012;**41**:D590–6. doi:10.1093/nar/gks1219.
- [30]. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014 1512 2014;**15**:1–21. doi:10.1186/S13059-014-0550-8.
- [31]. Patel P, Roper J. Gut microbiome composition is associated with COVID-19 disease severity. *Gastroenterology* 2021;**161**:722–4. doi:10.1053/J.GASTRO.2021.05.006.
- [32]. D D, A M. Gut microbiota and Covid-19- possible link and implications. *Virus Res* 2020;**285**. doi:10.1016/j.virusres.2020.198018.
- [33]. Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et al. Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. *Clin Infect Dis* 2020;**71**:2669–78. doi:10.1093/CID/CIAA709.
- [34]. Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. *Gastroenterology* 2020;**159**:944–55 e8. doi:10.1053/J.GASTRO.2020.05.048.
- [35]. Gou W, Fu Y, Yue L, Chen G, Cai X, Shuai M, et al. Gut microbiota, inflammation, and molecular signatures of host response to infection. *J Genet Genomics* 2021. doi:10.1016/J.JGG.2021.04.002.
- [36]. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. *Clin J Gastroenterol* 2018;**11**. doi:10.1007/S12328-017-0813-5.
- [37]. Braun T, Halevi S, Hadar R, Efroni G, Glick Saar E, Keller N, et al. SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition. *Sci Rep* 2021;**11**:8922. doi:10.1038/s41598-021-88536-6.
- [38]. De Maio F, Posteraro B, Ponziani FR., Cattani P., Gasbarrini A., Sanguinetti M. Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients n.d. 2021 https://doi.org/10.1186/s12575-020-00131-7.
- [39]. Liu J, Liu S, Zhang Z, Lee X, Wu W, Huang Z, et al. Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19. *Synth Syst Biotechnol* 2021;**6**:135–43. doi:10.1016/J.SYNBIO.2021.06.002.
- [40]. Mostafa HH, Fissel JA, Fanelli B, Bergman Y, Gniazdowski V, Dadlani M, et al. Metagenomic next-generation sequencing of nasopharyngeal specimens collected from confirmed and suspect covid-19 patients. *MBio* 2020;**11**:1–13. doi:10.1128/MBIO.01969-20.
- [41]. Engen PA, Naqib A, Jennings C, Green SJ, Landay A, Keshavarzian A, et al. Nasopharyngeal Microbiota in SARS-CoV-2 Positive and Negative Patients. *Biol Proced Online* 2021 231 2021;**23**:1–6. doi:10.1186/S12575-021-00148-6.
- [42]. Kalantar KL, Moazed F, Christenson SC, Wilson J, Deiss T, Belzer A, et al. Metagenomic comparison of tracheal aspirate and mini-bronchial alveolar lavage for assessment of respiratory microbiota. *Am J Physiol - Lung Cell Mol Physiol* 2019;**316**:L578–84. doi:10.1152/ajplung.00476.2018.
- [43]. Soltani S, Zakeri A, Zandi M, Kesheh MM, Tabibzadeh A, Dastranj M, et al. The role of bacterial and fungal human respiratory microbiota in COVID-19 patients. *Biomed Res Int* 2021 2021. doi:10.1155/2021/6670798.
- [44]. Ogunrinola GA, Oyewale JO, Oshamika OO, Olasehinde GI. The human microbiome and its impacts on health. *Int J Microbiol* 2020;**2020**. doi:10.1155/2020/8045646.
- [45]. Gaibani P, Viciani E, Bartoletti M, Lewis RE, Tonetti T, Lombardo D, et al. The lower respiratory tract microbiome of critically ill patients with COVID-19. *Sci Rep* 2021;**11**:10103. doi:10.1038/s41598-021-89516-6.